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Abstract
Background: This manuscript compares the efficacy and safety of duloxetine with placebo in
Taiwanese women with SUI.
Methods: Taiwanese women with SUI were were randomly assigned to placebo (n = 61) or
duloxetine 80 mg/day (n = 60) in this double-blind, 8-week, placebo-controlled study. Outcome
variables included: incontinence episode frequency (IEF), Incontinence Quality of Life questionnaire
(I-QOL) scores, and Patient Global Impression of Improvement rating (PGI-I).
Results: Decrease in IEF was significantly greater in duloxetine-treated than placebo-treated
women (69.98% vs 42.56%, P < .001). No treatment differences in I-QOL scores were significant.
There were significant differences in PGI-I rating. Treatment-emergent adverse events (TEAEs)
were experienced by more duloxetine-treated than placebo-treated women (80.0% vs 44.3%; P <
.001). Discontinuations due to adverse events were significantly greater for duloxetine-treated than
placebo-treated women (26.7% vs 6.6%; P = .003).
Conclusion: Data provide evidence for the safety and efficacy of duloxetine for the treatment for
Taiwanese women with SUI.
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Background
Until recently, treatment for stress urinary incontinence
(SUI), the involuntary leakage of urine on effort or exer-
tion, or on sneezing or coughing [1], has been limited to
behavioral interventions, pelvic floor muscle therapy,
devices, and/or surgery [2]. In August 2004, duloxetine
became the first medication approved for the treatment of
women with moderate to severe SUI throughout Europe,
portions of Central and South America, and the Middle
East. Duloxetine is the first and only pharmaceutical agent
to receive 1A rating from the International Continence
Society for the treatment of SUI in women.
Duloxetine is a dual serotonin and norepinephrine
reuptake inhibitor (SNRI) with little or no affinity for
cholinergic receptors. Animal studies have implicated
serotonin (5HT) and norepinephrine (NE) in the central
control of lower urinary tract function. In cats, serotoner-
gic agonists suppress parasympathetic activity and
enhance sympathetic and somatic activity in the lower uri-
nary tract [3-5] promoting urine storage by relaxing the
bladder and increasing outlet resistance. NE variably
affects the lower urinary tract depending on interactions
with appropriate adrenergic receptor subtypes [6-10] The
dual actions of duloxetine have been shown in the cat
model to increase bladder capacity and striated urethral
sphincter activity presumably through central actions in
the spinal cord[11]. The ability of duloxetine to centrally
stimulate pudendal motor neurons and increase striated
urethral sphincter tone and contractility is believed to be
the basis for its efficacy in women with SUI.
SUI is the most common type of urinary incontinence
(UI) in women [12] with approximately 78% of women
with UI presenting with the symptoms of SUI in either
pure or mixed forms [12]. In the United States, it is esti-
mated that 29.5 million women have SUI in a pure or
mixed form. The only available studies referring to Tai-
wanese women suggest that the prevalence of UI in Tai-
wanese women (ranging from 12–44%) is lower than that
of women in Western populations; however, differences
in study design and criteria make it difficult to compare
between studies [13-17].
Regulatory approval of duloxetine for the treatment of
women with SUI in other parts of the world has been
based on the demonstration of the safety and efficacy of
duloxetine in 4 randomized placebo-controlled core reg-
istration trials enrolling 1913 women from Africa, Aus-
tralia, Europe, and North and South America [18-21]. This
study was conducted in Taiwan as a supplement to the
existing core trials to comply with local regulatory require-
ments. The primary objective was to compare the efficacy
and safety of duloxetine 80 mg/day (administered as 40
mg twice daily) with that of placebo in the treatment of
Taiwanese women with predominant symptoms of SUI.
Methods
Non-pregnant women 20 years of age and older with pre-
dominant symptoms of SUI, were enrolled in this double-
blind, randomized, parallel, placebo-controlled, clinical
trial conducted at 9 study centers in Taiwan. Written
informed consent was obtained from all participants and
study design was reviewed by a local ethics committee in
accordance with the Declaration of Helsinki. Concomi-
tant medications including urinary continence promoting
drugs, antidepressants, drugs for obesity (including over-
the-counter appetite suppressants and diet pills), and
illicit drugs were not allowed in the study. Enrolled
women reported the predominant symptoms of SUI dur-
ing the last 3 months with an average of ≥ 1 incontinent
episode/day. Additional history requirements included
daytime voiding frequency ≤ 8 voids daily, nocturnal fre-
quency ≤ 2 voids daily and no predominant urge inconti-
nence symptoms. Women unable to tolerate retrograde
bladder filling to 400 mL or who had a first sensation of
bladder filling at ≤ 100 mL were excluded. A positive
cough stress test was required after filling the bladder.
The study design and timing of acquisition of diaries and
other variables are depicted in Figure 1. After a 2-week, no
drug, lead-in period, women were randomized to 80 mg
duloxetine (40 mg twice daily) or placebo for 8 weeks
Study design and the timing of acquisition of urinary diary and  quality of life measurements reported Figure 1
Study design and the timing of acquisition of urinary diary and 
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with post-randomization evaluation every 4 weeks. The
treatment phase of the core registration trials was 12
weeks; however, the majority of the these adverse events
emerged within the first 4 weeks and the number of
duloxetine responders (≥ 50% reduction in median per-
cent incontinence episode frequency [IEF]) did not
change significantly after 4 weeks post-randomization. An
8-week trial was therefore considered sufficient.
Randomization was controlled by a computerized interac-
tive voice response system at a central location for all
study sites. Stratified randomization using baseline IEF of
<14 or ≥14 episodes/week obtained from patient diaries
was used to prevent potential imbalance in incontinence
severity.
Weekly paper diaries were also used to collect the number
of voids, the time of voids, and the number of continence
pads used. Diaries were collected to determine baseline
incontinence severity the last week before visit 2 during
the no drug lead-in period (Figure 1).
The primary efficacy variable in this study was percent
change in IEF/week from baseline to endpoint, which was
calculated from subject completed, real-time, paper dia-
ries. Approximately 50% reduction in IEF has been gener-
ally accepted as a clinically relevant threshold for response
in SUI outcomes research for interventions including
bladder training and pelvic floor muscle training [22],
devices [23], surgery [24-26], and a pharmacological
agent [18-21]. An IEF responder was therefore defined as
a woman who had a > 50% decrease in IEF with treat-
ment.
Secondary efficacy variables included: 1) Incontinence
Quality of Life (I-QOL) questionnaire total and subscale
scores [27], 2) Patient Global Impression of Improvement
(PGI-I) rating[28], 3) mean time between voids/day, and
4) continence pad use/week.
The 22-item I-QOL questionnaire is a globally-validated
disease-specific instrument endorsed by the International
Consultation on Incontinence, which was administered at
each visit. The I-QOL questionnaire evaluates the effects
of UI in 3 domains: avoidance and limiting behavior,
social embarrassment, and psychosocial impact. An I-
QOL score of 100 represents the best possible quality of
life and 0 represents the worst possible quality of life. The
questionnaire has not been specifically validated in Chi-
nese language.
The PGI-I rating is a globally-validated 1-question ques-
tionnaire and was obtained at each post-randomization
visit. The PGI-I measures the improvement the subject
perceives in her condition since starting treatment [28].
The questionnaire has not been specifically validated in
Chinese language.
Compliance with the required study drug regiment was
examined at each visit following initiation of treatment.
Unused study drug was returned to Eli Lilly and Com-
pany, and compliance was assessed by counting returned
study drug. Investigators encouraged compliance with
study medication but subjects were not discontinued
from the study for poor compliance only.
Safety was assessed by evaluation of treatment-emergent
adverse events (TEAEs), discontinuations due to adverse
events, serious adverse events, discontinuation emergent
adverse events (DEAE), vital signs measurements, and
clinical laboratory tests. Adverse events were elicited by
nonprobing inquiry at each visit and were recorded
regardless of perceived causality. An event was considered
treatment emergent if it occurred for the first time or wors-
ened during the double-blind treatment period. DEAE
were adverse events that occurred following the end of the
treatment phase and were reported during the two week
follow up.
A serious adverse event was defined according to the Inter-
national Consultation on Harmonization guidelines and
included any adverse events associated with death, initial
or prolonged inpatient hospitalization, a life-threatening
experience (ie, immediate risk of dying), persistent or sig-
nificant disability/incapacity, congenital anomaly/birth
defect, or is significant for any other reason.
The statistical analysis plan was specified a priori and was
performed in accordance with intent-to-treat (ITT) prin-
ciples. Subjects with baseline and at least 1 post-baseline
measurement were included in the analysis. The percent
change in IEF was compared between treatment groups
using the van Elteren's test, a type of stratified Wilcoxon
test, with baseline incontinence severity as the stratifica-
tion variable. This primary analysis compared IEF before
and after randomization, pooling all diaries between vis-
its 1 and 2 for the baseline and all diaries between visits
2 and 4 for the end point. The changes in I-QOL scores
were analyzed using an ANCOVA model that included
terms for baseline scores, treatment, site, and baseline
incontinence severity. The endpoint PGI-I was analyzed
using the Cochran-Mantel-Haenszel test with the base-
line incontinence severity as the strata. The missing end-
point values in the above analyses were imputed via
LOCF.
Enrollment in the study was set to end when approxi-
mately 120 women (60 per treatment group) had been
assigned to a treatment group. The sample size was deter-
mined to provide 97.3% power for detecting a treatmentBMC Urology 2008, 8:2 http://www.biomedcentral.com/1471-2490/8/2
Page 4 of 9
(page number not for citation purposes)
difference of 23% in the median percent change in IEF
from baseline to endpoint.
Analyses were performed using SAS 8.1 (SAS Institute,
Cary, North Carolina). A two-sided alpha level of 0.05
was considered significant for treatment effects.
Results
A total of 121 women 30–79 years of age were randomly
assigned to receive duloxetine 80 mg/day (n = 60) or pla-
cebo (n = 61) between July 2003 and February 2005; over-
all 76.9% of women completed the 8-week study (66.7%
duloxetine, 86.9% placebo).
Baseline clinical characteristics of the women randomly
assigned to each treatment group were comparable (Table
1). There was a significant difference between treatment
group in height (duloxetine group was shorter on aver-
age), but there were no significant differences in body
mass indices (BMI) (Table 1). Additionally, women in the
duloxetine treatment group voided significantly more
often.
On average, patients in the placebo group took 86% of
their treatment doses compared with 68% of doses for
patients in the duloxetine group (P = .002). This differ-
ence in compliance was likely due to limited intake of
duloxetine by those subjects discontinuing early from the
trial and was not significant after the first post-randomiza-
tion visit.
The decrease in IEF, as demonstrated by median percent
change from baseline to endpoint, was significantly
greater in the duloxetine group than in the placebo group
(69.98% vs 42.56%, P  < .001; Table 2). The improve-
ments with duloxetine were observed at the first post-ran-
domization visit (4 weeks) and were maintained
throughout the study. Overall, there were significantly
more IEF responders within the duloxetine-treated
women than the placebo-treated women (69.6% vs
45.8%, respectively, P < .05).
In the secondary analyses, the median percent reduction
in continence pad use was numerically, but not signifi-
cantly, higher for the duloxetine-treated women com-
pared with those on placebo (-.67% vs .0%, P = .14). In
addition to decreasing their IEF, women in the duloxetine
group also numerically increased their average voiding
interval compared with those in the placebo group (11.85
minutes vs .01 minutes, P = .13). Improvements in mean
I-QOL total and subscales scores were apparent for both
the duloxetine- and placebo-treated groups, but separa-
tion between the groups was not statistically significant
(Tables 3 and 4). The analysis of PGI-I showed signifi-
cantly more duloxetine-treated subjects than placebo-
treated subjects rated their condition as "very much bet-
ter" and "much better".
TEAEs were experienced by more women in the duloxet-
ine group compared with the placebo group (80.0% vs
44.3%; P < .001). Table 5 lists all of the adverse events that
occurred in at least 5% of women on duloxetine or that
were significantly more common with duloxetine. The
very common adverse events (> 10% in either treatment
group) were constipation, dry mouth, nausea, somno-
lence, and dizziness. Most TEAEs were reported early in
the study, were mild to moderate in severity at onset, and
did not increase in severity. For subjects who remained in
the study despite experiencing a TEAE, the majority with
fatigue (80%), nausea (100%), and somnolence (57%)
had resolved within 30 days. Constipation, dry mouth,
and hyperhidrosis tended to persist longer than 30 days.
The discontinuation rate due to adverse events was signif-
icantly greater for the duloxetine group compared with
the placebo group (26.7% vs 6.6%; P = .003). Treatment
differences were not significant for any single event. The
most common adverse event leading to discontinuation
Table 1: Baseline† clinical characteristics for all randomized women. Data are mean (SD) unless otherwise indicated
Duloxetine Placebo
Randomized N‡ 60 61
Age, years 56.31 (± 11.00) 52.59 (± 10.25)
BMI, kg/m2 24.98 (± 2.96) 24.89 (± 3.13)
IEF/week (SD) [range] 15.38 (± 9.11) [5.50–47.44] 15.23 (± 8.74) [7.00–56.58]
Mean time between voids§ 179.36 (± 38.81) 193.32 (± 38.00)
I-QOL score 61.88 (± 19.84) 61.21 (± 22.71)
Previous continence surgery 3 5
†Baseline is the last visit score on or prior to randomization.
‡Every randomized subject did not provide information for each variable; percentages are calculated using the number of responding women as the 
denominator.
§P = 0.048.
Abbreviations: BMI = body mass index; PFMT = pelvic floor muscle training; IEF = incontinence episode frequency; I-QOL = Incontinence Quality of 
Life questionnaire.BMC Urology 2008, 8:2 http://www.biomedcentral.com/1471-2490/8/2
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(≥5% in the duloxetine treatment group) was dizziness.
Table 6 lists all adverse events that resulted in a >1% dis-
continuation rate for duloxetine.
Clinical laboratory assessments, vital signs, and physical
findings were stable relative to baseline and no clinically
relevant differences were detected between treatment
groups. A significant difference between treatment groups
was observed in the mean change in heart rate; however,
the 2.57 beat per minute (bpm) increase with duloxetine
was not considered clinically important. There was also a
significant 4.12 mmHg difference in the baseline to end-
point diastolic blood pressure between treatment groups,
but the 2.57 mmHg mean increase with duloxetine was
not considered clinically important.
Four duloxetine-treated subjects experienced 4 DEAEs,
while, placebo-treated subjects experienced 13 DEAEs.
Four subjects (1 duloxetine-treated and 3 placebo-treated)
experienced serious adverse events (SAEs). The reported
SAE in 1 duloxetine-treated subject was coronary artery
disease; the 3 SAEs reported in placebo-treated subjects
were eye injury, calculus ureteric, and a urinary tract infec-
tion. There were no deaths in this study.
Discussion
In this study of Taiwanese women with predominant SUI,
duloxetine 80 mg/day (40 mg twice daily) as measured by
the primary efficacy analysis (median percent change in
IEF/week) was noted to be significantly more effective
than placebo. Duloxetine was significantly superior to
placebo as measured by PGI-I responses, but there were
no differences between treatment groups for I-QOL total
or subscale scores. The significant reductions in IEF epi-
sodes and in PGI-I with duloxetine compared with pla-
cebo in this trial, are consistent with responses from
previously published core registration trials conducted in
Africa, Australia, Europe, and North and South America
[18-21].
Previous studies have shown that women with SUI begin
to appreciate that their condition has improved with treat-
ment when they reduce their incontinence by half [28].
There was a 50–100% reduction in incontinence episodes
in 69.6% of the Taiwanese women treated with duloxet-
Table 2: Incontinence episode frequency.
Treatment group (N)† Time point n‡ Median IEF/week Median percent change from 
baseline
95% CI for median 
percent change in IEF
P
Placebo (61) Baseline 59 14.00
Endpoint 6.25
Change -5.63 -42.56 (-56.79,-33.89)
Duloxetine (60) Baseline 46 13.46
Endpoint 4.12
Change -7.25 -69.98 (-81.25,-53.57) < .001
† N = number randomized.
‡ n = number with diary data available for specified analysis.
Abbreviations: CI = confidence interval; IEF = incontinence episode frequency.
Table 3: Incontinence Quality of Life questionnaire: total score.
I-QOL Total Score
Treatment group 
(N)†
Time point n‡ Mean I-QOL Mean change in I-
QOL from 
baseline§
95% CI for 
treatment 
difference in I-
QOL
P
Placebo (61) Baseline 59 61.23
Endpoint 74.56 13.33
Duloxetine (60) Baseline 52 62.65
Endpoint 76.29 13.64 (-4.77,6.78) .732
†N = number randomized.
‡n = number with diary data available for specified analysis.
§Baseline is the last nonmissing visit score on or before randomization.
¶95% CI for treatment difference.
Abbreviations: CI = confidence interval; I-QOL = Incontinence Quality of Life questionnaireBMC Urology 2008, 8:2 http://www.biomedcentral.com/1471-2490/8/2
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ine. In fact, the treatment difference of 23.8% for IEF
responders was somewhat greater than the treatment dif-
ferences observed in the analysis of the integrated data-
base from the 4 core registration trials [18-21]. Consistent
with the core registration trials, the significant duloxetine
group improvements in IEF were apparent within the first
4 weeks of treatment and were maintained throughout the
duration of the 8-week study.
Incontinence improved despite numerical but not statisti-
cally significant increases in the time between voids with
duloxetine, indicating the improvement did not result
from more frequent emptying of the bladder.
Although, I-QOL total and subscale scores improved in
women with both duloxetine and placebo-treated women
from baseline, the differences were not significant. The
overall improvement, but lack of separation between
treatments, despite significant treatment differences on
multiple other measures of efficacy, suggests that this
quality-of-life instrument may not be reflective of
improvements in incontinence either in its Chinese trans-
lation or in Taiwanese women. UI is often cited as a psy-
chologically distressing, socially secluding and potentially
disabling condition. In Western countries the impact of
UI on quality of life is comparable to the impact of diabe-
tes on quality of life [29,30]. A single study of Taiwanese
women suggests a greater impact on quality of life in Tai-
wanese women than in other cultures [14] and attributed
this to more stringent behavioral modifications in Taiwan
[14]. Nevertheless, the baseline, incontinence-specific
quality of life in these Taiwanese women, as measured by
I-QOL, was similar to that of Western women described in
an integrated analysis of 1913 women [18-21].
Table 4: Incontinence Quality of Life questionnaire: subscale scores.
I-QOL Avoidance and Limiting Behavior 
Subscale Score
I-QOL Psychological Impact Subscale 
Score
I-QOL Social Embarrassment Subscale 
Score
Treatment 
group (N)†
Time point n‡ Mean 
I-QOL
Mean 
change in 
I-QOL 
from 
baseline§
95% CI for 
treatment 
difference in 
I-QOL¶
P Mean 
I-QOL
Mean 
change in 
I-QOL 
from 
baseline§
95% CI for 
treatment 
difference in 
I-QOL¶
P Mean 
I-QOL
Mean 
change in 
I-QOL 
from 
baseline§
95% CI for 
treatment 
difference 
in IQOL¶
P
Placebo (61) Baseline 59 62.34 (-5.26,6.46) 64.22 (-3.73,7.89) 54.07 (-7.37,6.82)
Endpoint 75.16 12.82 76.22 12.01 70.59 16.53
Duloxetine (60) Baseline 52 63.28 66.72 54.33
Endpoint 75.96 12.68 .839 79.65 12.93 .480 70.77 16.44 .940
†N = number randomized.
‡n = number with diary data available for specified analysis.
§Baseline is the last nonmissing visit score on or before randomization.
¶95% CI for treatment difference.
Abbreviations: CI = confidence interval; I-QOL = Incontinence Quality of Life questionnaire
Table 5: TEAEs occurring in ≥ 5% of women randomized to duloxetine, or significantly more often with duloxetine than with placebo.
Duloxetine Placebo P
Values are expressed as n (%) (N = 60) (N = 61)
Total number of women with ≥ 1 TEAE 48 (80) 27 (44.3) < .001
Constipation 10 (16.7) 0 (0.0) .001
Dry mouth 10 (16.7) 2 (3.3) .016
Nausea 9 (15.0) 0 (0.0) .001
Somnolence 9 (15.0) 0 (0.0) .001
Dizziness 8 (13.3) 6 (9.8) .583
Fatigue 5 (8.3) 0 (0.0) .027
Hyperhidrosis 5 (8.3) 0 (0.0) .027
Cough 4 (6.7) 4 (6.6) > .999
Decreased appetite 4 (6.7) 1 (1.6) .207
Insomnia 4 (6.7) 2 (3.3) .439
Asthenia 3 (5.0) 1 (1.6) .365
Chest discomfort 3 (5.0) 3 (4.9) > .999
Palpations 3 (5.0) 2 (3.3) .680BMC Urology 2008, 8:2 http://www.biomedcentral.com/1471-2490/8/2
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Significantly more duloxetine-treated women than pla-
cebo-treated women experienced TEAEs with 26.7% of
duloxetine-treated women discontinuing therapy due to
adverse events. Unlike the core registration studies, this
study did not have a 2-week placebo lead-in phase which
may have increased the number of TEAEs reported relative
to those studies in which the discontinuation rate due to
adverse events was 20.5% for duloxetine-treated subjects.
Mean BMI in the Taiwanese women was lower than the
mean BMI in women included in the core studies which
could contribute to the increased number of women
reporting TEAEs and discontinuing.
Nausea was a frequent adverse event associated with
duloxetine treatment; 3.3% of all duloxetine patients dis-
continued due to nausea, although the majority of
women who experienced duloxetine-related nausea com-
pleted the study. Nausea tended to start soon after the ini-
tiation of duloxetine treatment. In most cases, nausea was
mild to moderate, did not worsen after its onset, and
resolved within 1 week to 1 month of therapy.
Overall, the majority of TEAEs reported by > 5% of
duloxetine-treated subjects and significantly more often
than in placebo-treated subjects, tended to be mild in
severity. One subject reported severe nausea. In no
instance did any of these TEAEs increase in severity. The
majority of women that experienced fatigue, nausea, and
somnolence but remained in the study had resolution of
the events within 30 days.
Constipation, dry mouth, and hyperhidrosis tended to
persist longer than 30 days. This TEAE profile is largely
consistent with published data from Africa, Australia,
Europe, and North and South America [18-21]. The
improvement associated with duloxetine treatment
should be weighed against a considerable discontinuation
rate due to early adverse events.
Conclusion
The data from this trial support the conclusion that
duloxetine has demonstrated similar efficacy and safety in
Taiwanese women with SUI as has been demonstrated in
women in Africa, Australia, Europe, and North and South
America. Duloxetine administered at 40 mg twice daily for
up to 8 weeks for the treatment of Taiwanese women with
SUI is safe and efficacious. Finally, the data also support
the conclusion that the findings from studies in other
populations, with the exception of I-QOL, can be reason-
ably extrapolated to the Taiwanese population.
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